Genetic Signatures Ltd. · ASX:GSS
Genetic Signatures — Investor Presentation (September 2026)
16 slides from Genetic Signatures's investor presentation, Sep 22, 2026
Slide 1: Investor Presentation - Proposed Merger with Microba Life Sciences
ASX Announcement 22 September 2026 Investor Presentation - Proposed Merger with Microba Life Sciences Genetic Signatures Limited (ASX:GSS) is pleased to provide the attached investor presentation regarding the proposed merger with Microba Life Sciences Limited (ASX:MAP). The presentation outlines th
Slide 2: Proposed Microba Merger Presentation
Proposed Microba Merger Presentation 22 September 2026 1
Slide 3: A Transformative Merger
A Transformative Merger Proposed Microba Merger Combining two complementary Australian diagnostics businesses to create a scaled, cash-backed ASX-listed group serving an expanded gastrointestinal testing pathway ✓ Creates a scaled ASX-listed diagnostics group • Approximately $30 million of combined
Slide 4: Transaction Summary
Transaction Summary Proposed Microba Merger GSS to acquire 100% of Microba Life Sciences by scheme of arrangement, funded entirely in GSS scrip • GSS acquires 100% of the issued shares in Microba Life Sciences (ASX: MAP) by scheme of arrangement under Part 5.1 Structure of the Corporations Act. The
Slide 5: Strategic Rationale & Financial Benefits
Strategic Rationale & Financial Benefits Proposed Microba Merger Four key reasons the Board considers the merger to be in the interests of GSS shareholders Significantly Materially Wider Financially Attractive Well Positioned for Enhanced Scale Route to Market Combination Future Growth • Approximate
Slide 6: Overview of Microba Life Sciences
Overview of Microba Life Sciences Proposed Microba Merger Microba is an ASX-listed precision microbiome company with clinical testing in Australia and the UK, a supplements business and a live biotherapeutics pipeline 1 Metagenomic Diagnostics 2 Channels & Partners • Microbiome Explorer and MetaPane
Slide 7: Complementary Footprints & Customer Base
Complementary Footprints & Customer Base Proposed Microba Merger A single group spanning hospital laboratories, clinician networks and distribution in more than 30 countries Australia United Kingdom Europe USA and rest of world • GSS manufacturing in • GSS NHS and hospital • GSS ten-year supply • GS
Slide 8: Minimum Cost Synergies Expected from Merger
Minimum Cost Synergies Expected from Merger Proposed Microba Merger Duplicated listed-company and corporate costs provide a minimum level of synergies from the deal ~$0.9m ~$1.9m ~$0.2m Listed-entity and public-company Duplicated corporate and G&A Infrastructure and professional costs functions serv
Slide 9: Combined Company Contribution Analysis
Combined Company Contribution Analysis Proposed Microba Merger Genetic Signatures contributes the majority of the cash and net assets while Microba contributes the majority of near-term growth Genetic Contribution Microba Total MAP % GSS % Signatures Shares on Issue / Ownership merged group ~469m ~2
Slide 10: Recap: Key Benefits of Merger
Recap: Key Benefits of Merger Proposed Microba Merger 1 Significantly enhanced scale 2 A materially wider route to market Creates a scaled ASX-listed leader in gastrointestinal and infectious disease diagnostics, for the benefit of A more financially attractive combination that is patients, laborato
Slide 11: Indicative Timetable
Indicative Timetable Proposed Microba Merger Event Indicative date Despatch of the GSS Notice of Meeting late September 2026 Convene GSS shareholder meeting to approve Proposed Merger October 2026 Execution of the Scheme Implementation Deed (subject to receiving GSS shareholder approval) October 202
Slide 12: Conditions & Approvals
Conditions & Approvals Proposed Microba Merger Conditions to implementation • Receipt of any required ASX confirmations or approvals. • GSS shareholder approval to proceed with the Proposed Merger and issue the relevant consideration securities. • Finalisation and execution of a definitive Scheme Im
Slide 13: Key Risks
Key Risks Proposed Microba Merger Integration and synergy realisation Forecast risk Estimated synergies may not be achieved in full or on the timetable The combined forecasts rest on management projections for both assumed, and one-off costs to achieve them may exceed estimates. businesses. Residual
Slide 14: Important Notice
Important Notice Proposed Microba Merger Important Notice This presentation has been prepared by Adelaide Equity Partners Limited t/a AE Advisors on behalf of Genetic Signatures Limited (GSS). Summary information This presentation contains summary information about GSS and its activities current as
Slide 15: Important Notice
Important Notice Proposed Microba Merger Future performance Forward-looking statements are statements about matters that are not historical facts. Forward-looking statements appear in a number of places in this presentation and include statements regarding GSS’s intent, belief or current expectation
Slide 16: Contact us
Contact us P: +61 (0)2 9870 7580 E: info@geneticsignatures.com Visit us geneticsignatures.com Follow us 15
Genetic Signatures — Investor Presentation (September 2026) on 6ix